News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,164 Results
Type
Article (41925)
Company Profile (435)
Press Release (664804)
Section
Business (208573)
Career Advice (2016)
Deals (35984)
Drug Delivery (98)
Drug Development (83468)
Employer Resources (170)
FDA (16373)
Job Trends (15069)
News (352450)
Policy (33015)
Tag
Academia (2620)
Alliances (50832)
Alzheimer's disease (1347)
Approvals (16331)
Artificial intelligence (205)
Bankruptcy (365)
Best Places to Work (11841)
Biotechnology (329)
Breast cancer (221)
Cancer (1665)
Cardiovascular disease (132)
Career advice (1681)
CAR-T (118)
Cell therapy (347)
Clinical research (66909)
Collaboration (659)
Compensation (344)
COVID-19 (2616)
C-suite (153)
Data (1553)
Diabetes (208)
Diagnostics (6307)
Earnings (86437)
Employer resources (147)
Events (114168)
Executive appointments (550)
FDA (17225)
Funding (592)
Gene therapy (247)
GLP-1 (677)
Government (4439)
Healthcare (19085)
Infectious disease (2721)
Inflammatory bowel disease (123)
Interviews (309)
IPO (16718)
Job creations (3698)
Job search strategy (1431)
Layoffs (461)
Legal (7956)
Lung cancer (248)
Manufacturing (235)
Medical device (13398)
Medtech (13403)
Mergers & acquisitions (19594)
Metabolic disorders (560)
Neuroscience (1765)
NextGen: Class of 2025 (6750)
Non-profit (4549)
Northern California (1987)
Obesity (319)
Opinion (209)
Patents (144)
People (58134)
Phase I (21015)
Phase II (29541)
Phase III (21819)
Pipeline (669)
Postmarket research (2600)
Preclinical (8961)
Radiopharmaceuticals (257)
Rare diseases (326)
Real estate (6002)
Regulatory (22304)
Research institute (2406)
Resumes & cover letters (351)
Southern California (1736)
Startups (3753)
United States (18144)
Vaccines (620)
Weight loss (222)
Date
Today (112)
Last 7 days (636)
Last 30 days (2760)
Last 365 days (35702)
2025 (3356)
2024 (36304)
2023 (41017)
2022 (52279)
2021 (56770)
2020 (54927)
2019 (47424)
2018 (35702)
2017 (33031)
2016 (32352)
2015 (38402)
2014 (32188)
2013 (27111)
2012 (29225)
2011 (29865)
2010 (27993)
Location
Africa (733)
Arizona (215)
Asia (38862)
Australia (6469)
California (4623)
Canada (1646)
China (382)
Colorado (210)
Connecticut (225)
Europe (84810)
Florida (662)
Georgia (158)
Illinois (461)
Indiana (255)
Maryland (733)
Massachusetts (3620)
Michigan (196)
Minnesota (332)
New Jersey (1308)
New York (1311)
North Carolina (873)
Northern California (1987)
Ohio (166)
Pennsylvania (1069)
South America (1107)
Southern California (1736)
Texas (676)
Utah (139)
Washington State (468)
707,164 Results for "allos therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
January 23, 2025
·
4 min read
Press Releases
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
January 28, 2025
·
7 min read
Press Releases
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
December 9, 2024
·
12 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
December 9, 2024
·
9 min read
Biotech Beach
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.
March 13, 2024
·
6 min read
Press Releases
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
November 7, 2024
·
11 min read
Genetown
Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen
Allos Pharma Inc., a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced that it has expanded its intellectual property rights with a new patent family.
September 18, 2023
·
2 min read
Drug Development
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1.
April 8, 2024
·
9 min read
Press Releases
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
November 18, 2024
·
7 min read
1 of 70,717
Next
